Roivant plans sNDA for brepocitinib in non-infectious uveitis in H1 2027

Roivant plans to submit a supplemental new drug application (sNDA) for brepocitinib in non-infectious uveitis in the first half of 2027.

Detected & updated continuously · Source: Nebula